SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

June 9, 2020

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Latest News

C difficile Awareness Month: Breakthroughs and Setbacks

C difficile, Antimicrobials, and the Patients Most Affected

European Commission Approves Sanofi-GSK COVID-19 Booster VidPrevtyn

Genetic Factors That Naturally Protect Against Severe COVID-19

View More News